Articles published by Can-Fite BioPharma Ltd.

Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

March 16, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

March 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo

February 14, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

January 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

January 11, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow

January 10, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces ADS Ratio Change

December 30, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer

December 28, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

December 08, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update

November 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

November 02, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®

October 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

October 13, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

September 12, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update

August 25, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

August 23, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix

August 17, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress

August 22, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

July 11, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis

June 29, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia

June 24, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal

June 09, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update

May 26, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Granted Key NASH Patent in Israel

May 16, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit

May 02, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug

April 05, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

March 28, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports 2021 Financial Results & Provides Clinical Update

March 24, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

March 14, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

January 31, 2022

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.